Endovia Health Sciences, Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Endovia Health Sciences issued a secured convertible promissory note for $510,000 principal (with $576,271 original issue discount amount) to C/M Capital Master Fund, LP on September 18, 2026. The note converts at $1.75/share (or $0.01 above closing price, whichever is lower), matures in 12 months, bears 7% interest on default, and is secured by all company assets with priority over all existing/future debt except related-party obligations ranking pari passu. The investment supports commercialization of a licensed product under an exclusive license agreement with Argent Biopharma Limited dated July 2, 2026.
Why this rating
Major dilutive financing for $6.5M company; 30% of proceeds must repay note; extensive investor protections and conversion rights; governance restrictions; conversion could substantially dilute equity.
Price action (we called it negative)
before filing · preread $0.19 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.